Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees

M. Schley, S. Topfner, K. Wiech, H. E. Schaller, C. J. Konrad, M. Schmelz, N. Birbaumer

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Background: Hyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP). Aim of the study: To investigate whether early treatment with the NMDA antagonist memantine attenuates phantom pain memory formation in traumatic amputees. Methods: In a randomized, double-blind, controlled trial 19 patients with acute traumatic amputation of the upper extremity were investigated. All patients received postoperative analgesia by continuous brachial plexus anesthesia (ropivacaine 0.375% 5 ml/h) for at least 7 days. In addition, the patients received either memantine (20-30 mg daily, n = 10) or placebo (n = 9) for 4 weeks. Results: Memantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up. Conclusions: We conclude that memantine can reduce intensity of phantom limb pain and might also prevent the development of PLP. However, despite the very early begin of treatment; no long-term effect on established PLP was evident.

Original languageEnglish
Pages (from-to)299-308
Number of pages10
JournalEuropean Journal of Pain (United Kingdom)
Volume11
Issue number3
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Phantom Limb
Memantine
Amputees
Upper Extremity
Acids
Traumatic Amputation
Aspartic Acid
Analgesia
Brachial Plexus Block
aspartic acid receptor
Therapeutics
Placebos
Injections

Keywords

  • Acute traumatic amputation
  • Continuous brachial plexus block
  • Deafferentation hyperexcitability
  • Glutamate antagonism

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Neuropsychology and Physiological Psychology

Cite this

Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. / Schley, M.; Topfner, S.; Wiech, K.; Schaller, H. E.; Konrad, C. J.; Schmelz, M.; Birbaumer, N.

In: European Journal of Pain (United Kingdom), Vol. 11, No. 3, 04.2007, p. 299-308.

Research output: Contribution to journalArticle

Schley, M. ; Topfner, S. ; Wiech, K. ; Schaller, H. E. ; Konrad, C. J. ; Schmelz, M. ; Birbaumer, N. / Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. In: European Journal of Pain (United Kingdom). 2007 ; Vol. 11, No. 3. pp. 299-308.
@article{af3b36b2ce3c4f3287ab5c928c8017ab,
title = "Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees",
abstract = "Background: Hyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP). Aim of the study: To investigate whether early treatment with the NMDA antagonist memantine attenuates phantom pain memory formation in traumatic amputees. Methods: In a randomized, double-blind, controlled trial 19 patients with acute traumatic amputation of the upper extremity were investigated. All patients received postoperative analgesia by continuous brachial plexus anesthesia (ropivacaine 0.375{\%} 5 ml/h) for at least 7 days. In addition, the patients received either memantine (20-30 mg daily, n = 10) or placebo (n = 9) for 4 weeks. Results: Memantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up. Conclusions: We conclude that memantine can reduce intensity of phantom limb pain and might also prevent the development of PLP. However, despite the very early begin of treatment; no long-term effect on established PLP was evident.",
keywords = "Acute traumatic amputation, Continuous brachial plexus block, Deafferentation hyperexcitability, Glutamate antagonism",
author = "M. Schley and S. Topfner and K. Wiech and Schaller, {H. E.} and Konrad, {C. J.} and M. Schmelz and N. Birbaumer",
year = "2007",
month = "4",
doi = "10.1016/j.ejpain.2006.03.003",
language = "English",
volume = "11",
pages = "299--308",
journal = "EUR.J.PAIN",
issn = "1090-3801",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees

AU - Schley, M.

AU - Topfner, S.

AU - Wiech, K.

AU - Schaller, H. E.

AU - Konrad, C. J.

AU - Schmelz, M.

AU - Birbaumer, N.

PY - 2007/4

Y1 - 2007/4

N2 - Background: Hyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP). Aim of the study: To investigate whether early treatment with the NMDA antagonist memantine attenuates phantom pain memory formation in traumatic amputees. Methods: In a randomized, double-blind, controlled trial 19 patients with acute traumatic amputation of the upper extremity were investigated. All patients received postoperative analgesia by continuous brachial plexus anesthesia (ropivacaine 0.375% 5 ml/h) for at least 7 days. In addition, the patients received either memantine (20-30 mg daily, n = 10) or placebo (n = 9) for 4 weeks. Results: Memantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up. Conclusions: We conclude that memantine can reduce intensity of phantom limb pain and might also prevent the development of PLP. However, despite the very early begin of treatment; no long-term effect on established PLP was evident.

AB - Background: Hyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP). Aim of the study: To investigate whether early treatment with the NMDA antagonist memantine attenuates phantom pain memory formation in traumatic amputees. Methods: In a randomized, double-blind, controlled trial 19 patients with acute traumatic amputation of the upper extremity were investigated. All patients received postoperative analgesia by continuous brachial plexus anesthesia (ropivacaine 0.375% 5 ml/h) for at least 7 days. In addition, the patients received either memantine (20-30 mg daily, n = 10) or placebo (n = 9) for 4 weeks. Results: Memantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up. Conclusions: We conclude that memantine can reduce intensity of phantom limb pain and might also prevent the development of PLP. However, despite the very early begin of treatment; no long-term effect on established PLP was evident.

KW - Acute traumatic amputation

KW - Continuous brachial plexus block

KW - Deafferentation hyperexcitability

KW - Glutamate antagonism

UR - http://www.scopus.com/inward/record.url?scp=33846817366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846817366&partnerID=8YFLogxK

U2 - 10.1016/j.ejpain.2006.03.003

DO - 10.1016/j.ejpain.2006.03.003

M3 - Article

C2 - 16716615

AN - SCOPUS:33846817366

VL - 11

SP - 299

EP - 308

JO - EUR.J.PAIN

JF - EUR.J.PAIN

SN - 1090-3801

IS - 3

ER -